Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heron Therapeutics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

Recent & Breaking News (NDAQ:HRTX)

Watch These 5 Huge Call Purchases In Wednesday Trade

Benzinga.com  August 9, 2017

Drug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics

PR Newswire July 26, 2017

Research Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera Sciences

PR Newswire June 2, 2017

Heron Therapeutics to Present at the Jefferies 2017 Healthcare Conference

Business Wire May 30, 2017

Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress

Business Wire May 10, 2017

Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference

Business Wire May 9, 2017

Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance

Business Wire April 24, 2017

Heron Therapeutics to Present at the 16th Annual Needham Healthcare Conference

Business Wire March 28, 2017

How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron Therapeutics, and GW Pharma

PR Newswire March 14, 2017

Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

Business Wire March 13, 2017

Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference

Business Wire February 28, 2017

Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines

Business Wire February 24, 2017

Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress

Business Wire February 23, 2017

Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Business Wire February 8, 2017

Research Reports Coverage on Drug Makers Stocks -- Sanofi, Impax Labs, Heron Therapeutics, and Biostar Pharma

PR Newswire February 6, 2017

Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares

Business Wire January 31, 2017

Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Business Wire January 19, 2017

Heron Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire January 18, 2017

7 Biotech Catalysts Remaining In January

Benzinga.com  January 13, 2017

Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Business Wire January 12, 2017